| Literature DB >> 28798772 |
Victor V Revin1, Antonina A Ushakova1, Natalia V Gromova1, Larisa A Balykova1, Elvira S Revina1, Vera V Stolyarova1, Tatiana A Stolbova1, Ilya N Solomadin1, Alexander Yu Tychkov1, Nadezhda V Revina1, Oksana G Imarova2.
Abstract
The current study investigates the functional state of erythrocytes and indices of the oxygen-binding capacity of hemoglobin in blood samples from healthy donors and from patients with coronary artery disease and myocardial infarction before and after treatment. It has been established that, in cardiovascular diseases, erythrocyte morphology and hemoglobin oxygen-transporting disorders are observed. Standard therapy does not result in the restoration of the structure and properties of erythrocytes. The authors believe that it is necessary for future therapeutic treatment to include preparations other than cardiovascular agents to enhance the capacity of hemoglobin to transport oxygen to the tissues.Entities:
Year: 2017 PMID: 28798772 PMCID: PMC5535697 DOI: 10.1155/2017/8964587
Source DB: PubMed Journal: Adv Hematol
RBC count and erythrocyte indices in the blood of apparently healthy people and in patients with SA and MI before and after treatment, n = 20 (М ± SD).
| Test groups | Indices | |||
|---|---|---|---|---|
| RBС count (3.8–5.3) × 1012cells/L | MСV (80–100) fL (femtolitre) | MСH in one erythrocyte (27–32) рg (picogram) | MСHС (320–360) рg (picogram) | |
| Control | 4.47 ± 0.20 | 94.51 ± 4.41 | 31.17 ± 1.18 | 343.3 ± 8.23 |
| SA patients before treatment | 4.87 ± 0.41 | 88.37 ± 4.09 | 29.98 ± 1.06 | 330.6 ± 20.45 |
| SA patients after treatment | 4.75 ± 0.34 | 90.35 ± 4.81 | 30.09 ± 1.20 | 332.0 ± 3.66 |
| MI patients before treatment | 4.76 ± 0.31 | 88.3 ± 4.14 | 29.54 ± 1.63 | 329.3 ± 12.57 |
| MI patients after treatment | 4.52 ± 0.45 | 90.12 ± 2.74 | 30.22 ± 1.03 | 333.85 ± 12.29 |
p < 0.05; p < 0.01.
Morphometric characteristics of erythrocytes from apparently healthy people and from patients with SA and MI before and after treatment, n = 20 (М ± SD).
| Test groups | Indices | |||
|---|---|---|---|---|
| The mean value of optical path difference (OPD), Φmean, nm | Phase image area of erythrocyte, | Geometric mean height of the erythrocyte, | Erythrocyte phase volume, | |
| Control | 151.82 ± 6.46 | 43.43 ± 3.79 | 2.02 ± 0.11 | 87.73 ± 4.82 |
| SA patients before treatment | 177.39 ± 5.39 | 40.80 ± 3.30 | 2.36 ± 0.14 | 96.29 ± 3.55 |
| SA patients after treatment | 115.38 ± 4.61 | 55.99 ± 2.93 | 1.53 ± 0.11 | 75.59 ± 3.99 |
| MI patients before treatment | 187.53 ± 6.41 | 40.66 ± 2.90 | 2.50 ± 0.15 | 101.65 ± 2.98 |
| MI patients after treatment | 114.39 ± 3.82 | 59.40 ± 2.25Δ | 1.52 ± 0.14 | 74.25 ± 4.46Δ |
p < 0.05, reliability in relation to donors' indicators; Δp < 0.05, reliability in relation to pretreatment indicators.
Figure 1Phase images of erythrocytes, taken using LIM (oX, oY: erythrocyte sizes, μm; oZ: optical path difference (OPD), nm): (a) erythrocyte from a healthy donor (discocyte); (b) erythrocyte from a MI patient before treatment (spherocyte); (c) erythrocyte from a SA patient before treatment (stomatocyte); (d) erythrocyte from a MI patient after treatment (stomatocyte).
Figure 2Spectrum of Raman scattering of hematoporphyrin hemoglobin. The figure shows the Raman bands with the position of the maximums of 1355, 1375, 1550, and 1580 cm−1. The ordinate is the intensity of the Raman radiation, in conventional units; along the abscissa-frequency shift, cm−1.
Correlation of Raman bands of erythrocyte hemoglobin hematoporphyrin of apparently healthy people and people with SA and MI before and after treatment, n = 20 (М ± SD).
| Test groups | Indices | |||
|---|---|---|---|---|
| Percentage of oxyhemoglobin blood | Relative ability of hemoglobin to bind ligands | Relative ability of hemoglobin to drop off ligands | Hemoglobin ligand affinity (О2) ( | |
| Control | 0.69 ± 0.03 | 0.61 ± 0.03 | 0.53 ± 0.02 | 1.16 ± 0.07 |
| SA patients before treatment | 0.54 ± 0.02 | 0.70 ± 0.03 | 0.44 ± 0.03 | 1.56 ± 0.12 |
| SA patients after treatment | 0.61 ± 0.03 | 0.67 ± 0.04 | 0.48 ± 0.03 | 1.41 ± 0.15 |
| MI patients before treatment | 0.52 ± 0.03 | 0.76 ± 0.03 | 0.40 ± 0.02 | 1.90 ± 0.11 |
| MI patients after treatment | 0.58 ± 0.04 | 0.75 ± 0.05 | 0.42 ± 0.03 | 1.52 ± 0.10 |
p < 0.05, reliability in relation to donors' indicators; Δp < 0.05, reliability in relation to pretreatment indicators.